Central Precocious Puberty (CPP) is a condition driven by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, manifesting before the age of 8 in girls and 9 in boys. This syndrome is characterized by the pulsatile secretion of gonadotropins (LH/FSH) and the subsequent overproduction of sex steroids, which accelerates linear growth, hastens skeletal maturation, and triggers the early development of secondary sexual characteristics.
Etiologically, CPP can be either idiopathic or organic (secondary to central nervous system lesions, such as hypothalamic hamartomas or tumors). Crucially, isolated thelarche or isolated adrenarche do not constitute true precocious puberty. Consequently, the clinician’s primary objective is to differentiate progressive disorders from isolated, non-progressive variants.
To address these diagnostic challenges and reduce unnecessary medical interventions, the Endocrine Society has developed new clinical practice guidelines. Compiled utilizing the GRADE framework, these recommendations are predominantly designated as conditional (GRADE 2) due to a paucity of randomized controlled trials, relying instead on observational data and consensus expert opinion.
Core Diagnostic Framework for Clinicians
The updated approach favors individualized assessment of patient status and the rate of pubertal progression over reflexive, standardized laboratory testing.
The Watchful Waiting Strategy: In girls aged 7 to 8 presenting with isolated breast development (Tanner Stage II) and no neurological symptoms, experts recommend watchful waiting. Periodic clinical evaluations every 4 to 6 months are sufficient. This conservative management is justified by the frequently transient or slowly progressive nature of symptoms in this age bracket, combined with a lack of robust clinical data demonstrating a clear benefit of early pharmacotherapy.
Indications for Active Investigation: In girls under 8, an active diagnostic workup is warranted if the initial evaluation reveals advanced pubertal signs (Tanner Stage ≥III), documentable progression over time, or a pathological acceleration in growth velocity (greater than 6 cm/year).
Management in Younger Cohorts: For girls under the age of 7 at the onset of isolated thelarche, experts still recommend an initial 4-to-6-month observational window. However, diagnostic restrictions are lifted immediately upon the appearance of any alarming clinical signs. In this specific population, rapid progression is defined as the advancement to Tanner Stage III within 6 months of the larche onset. Thus, a presentation of Tanner Stage ≥III at the initial visit, subsequent clinical progression, or an accelerated growth trajectory justifies an expanded diagnostic workup.
A key innovation within this guideline is a stepped laboratory algorithm that eliminates the routine use of a GnRH or GnRHa stimulation test as a first-line diagnostic tool.
Laboratory Requirement: The assays deployed in clinical practice must be ultrasensitive, capable of accurately detecting minimum hormone concentrations down to less than 0.05–0.1 IU/L. An elevated basal LH level (approximately greater than 0.2–0.3 IU/L) in a girl with Tanner Stage II–III development confirms HPG axis activation, rendering stimulatory testing unnecessary.
Neuroimaging and Genetics: Criteria for Selective Workup
The indications for brain imaging have been narrowed significantly.
In girls aged 6 to 8 and boys aged 8 to 9 with confirmed CPP, a brain MRI should not be performed routinely in the absence of neurological signs or symptoms. Multicenter cohort studies indicate an exceedingly low prevalence of intracranial pathology (such as tumors or hamartomas) in these age groups—occurring in approximately 1% of girls and approaching 0% in boys.
Conversely, the incidence of organic CNS lesions is substantially higher in younger children and in boys under 8 years of age. Furthermore, routine MRIs frequently uncover incidental, non-pathological findings that fuel parental anxiety and prompt unnecessary follow-up imaging. Neuroimaging remains mandatory for any child presenting with focal neurological signs (e.g., headaches, seizures, visual field defects) or an ultra-early age of pubertal onset. If parents express a strong preference for imaging to gain reassurance, the decision should be made via shared clinical decision-making.
Genetic Testing
Routine genetic screening (MKRN3, DLK1, MECP2) is not recommended for all patients. While experts acknowledge that MKRN3 mutations account for roughly 9% of idiopathic cases and 33–46% of familial forms (and DLK1 variants may elevate metabolic risks), robust evidence demonstrating that routine screening improves clinical outcomes is lacking.
Potential downsides include psychological distress, the detection of variants of uncertain significance (VUS), limited availability, and high cost. Specific genetic testing should be reserved selectively for patients with a documented family history, syndromic features, or neurodevelopmental disorders, following a detailed discussion of the anticipated utility and systemic barriers.
Therapeutics: Indications, Benefits, and Potential Harms
The guideline supports the use of gonadotropin-releasing hormone agonist (GnRHa) therapy for many children with confirmed, progressive CPP, but cautions against universal application.
Impact on Adult Height: The primary goal of intervention is the preservation of adult height potential. Pooled data from 15 observational studies indicate that GnRHa therapy yields a mean increase in final adult height of 2 to 4 cm. This therapeutic benefit is most pronounced when treatment is initiated at an early age and maintained long-term (≥3 years).
Secondary Outcomes: Adult Body Mass Index (BMI) does not differ significantly between treated and untreated cohorts. Data regarding long-term bone mineral density (BMD), reproductive function, neurocognitive development, and psychosocial outcomes remain sparse. In treated girls, menarche is deferred by approximately 1 to 2 years, an outcome that many families view favorably.
Safety Profile: Adverse events are generally rare and mild, typically limited to injection site pain or sterile abscesses. However, the risk of developing Idiopathic Intracranial Hypertension (IIH) has been officially added to the safety profile. This potential complication necessitates clinical vigilance for symptoms such as headaches, visual disturbances, and papilledema.
When Treatment is Ineffective: In girls aged 7 to 8 with slowly progressive CPP, initiating GnRHa therapy provides no clinical benefit in terms of height gain. Treatment is similarly ineffective in children who, based on bone age assessment, are already at or beyond their pubertal growth peak.
Given the low certainty of scientific evidence and the high financial burden of these medications, the panel issues a conditional recommendation for the use of GnRHa therapy. The treatment plan must be established through shared decision-making with the family, balancing predicted height gains, psychosocial factors, preferred timing of menarche, and financial costs.
Formulation Selection and Monitoring Strategies
When initiating treatment in patients requiring long-term therapy, the guideline recommends utilizing long-acting (depot) formulations from the outset. Consolidated data show no clinically meaningful differences between monthly and long-acting (≥3-month) depot formulations regarding stimulated LH levels, the depth of hormonal suppression, or growth velocity. Long-acting formulations significantly lower injection frequency, thereby enhancing treatment adherence.
The guideline advocates for a shift away from routine biochemical monitoring during therapy.
Adjunctive Growth Hormone and Treatment Cessation
The routine addition of growth hormone (GH) to GnRHa therapy in children with CPP is not recommended. Combined therapy offers no substantial clinical advantage over GnRHa monotherapy regarding final adult height, while significantly inflating both the risk of adverse effects and financial expenditures.
GH co-administration should be restricted to patients with distinct, independent medical indications, such as comorbid growth hormone deficiency or being born small for gestational age (SGA). Its use as an adjunctive agent may be considered only in exceptional circumstances, such as an exceptionally poor predicted adult height trajectory, following extensive specialist consultation with the family.
Regarding the discontinuation of therapy, the guideline advises against the routine extension of GnRHa treatment once a child reaches an appropriate age or skeletal threshold:
Chronological Age Threshold: Approximately 10–11 years for girls; 11–12 years for boys.
Bone Age Threshold: Approximately 11–12 years for girls; 12–13 years for boys.
There is no literature suggesting that extending treatment beyond these milestones improves clinical outcomes. The final decision to discontinue therapy must be tailored individually, taking into account the child’s growth trajectory, psychosocial factors, and any underlying conditions (such as developmental delay). Clinicians must evaluate chronological and bone age collectively within a comprehensive clinical framework, rather than in isolation.
Strengths, Limitations, and Clinical Impact
The principal strength of this work lies in its pragmatic, transparent approach to addressing existing scientific gaps, emphasizing the rational utilization of medical resources, healthcare accessibility, and clinical utility. These conditional recommendations empower clinicians to curb redundant testing and restrict interventions to patient populations poised to derive measurable benefit. Furthermore, the expert panel successfully integrates data from modern, multicenter neuroimaging cohorts and expands our understanding of the genetic foundations of CPP.
Conversely, a major limitation of the guideline is the scarcity of high-quality randomized controlled trials, forcing the authors to rely on observational datasets and heterogeneous meta-analyses. Additionally, diagnostic biochemical cutoffs remain highly dependent on specific laboratory assays and the technical capabilities of local centers. Finally, there remains a pronounced deficit in data concerning male cohorts, alongside a lack of robust, long-term evidence regarding psychosocial, reproductive, skeletal, and cardiometabolic outcomes. Clinicians must carefully adapt these guidelines to accommodate local healthcare infrastructure and individual patient dynamics.
The complete guideline can be accessed via JCEM
